未找到相关数据
Result of an open-label phase 2 trial of dual TORC1/TORC2 inhibitor onatasertib (ATG-008) in HBV+ advanced hepatocellular carcinoma (HCC) subjects who have received at least one prior line of systemic therapy (TORCH)
被引：1
作者：
Qin, Shukui
Lin, Xiaoyan
Meng, Zhiqaing
Ren, Zhenggang
Bai, Yuxian
Gu, Shanzhi
Zheng, Li
Li, Qiu
Oh, Sun-Yong
Guo, Yabing
Kang, Yoong-Koo
Kao, Wei-Yu
Li, Wei
Yoon, Jung-Hwan
Zhang, Helong
Chen, Pei-Jer
Yang, Tsai-Sheng
Heo, Jeong
Zheng, Zhendong
Xie, Hui
Yu, Zhinuan
机构：
关键词：
D O I：
10.1158/1538-7445.AM2023-CT150
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT150
引用
收藏
页数：3
相关论文